AUTHORS
Yi He, MD, Xiaoyu Zhang, MD2, Guangyu Sun, MD3, Nainong Li, MD4, Xiaoxia Hu, MD5, Xiao-Dong Mo, MD6, Weijie Cao7, Yang Cao, MD8, Ying Zhang, PhD9, Xiaoyu Zhu, MD10, Erlie Jiang, MD11
AFFILIATIONS
1 State Key Laboratory of Experimental Hematology, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, National Clinical Research Center for Blood Diseases, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
2 State Key Laboratory of Experimental Hematology, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, National Clinical Research Center for Blood Diseases, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
3 Department of Hematology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China, hefei, China
4 Department of Hematology, Hematopoietic Stem Cell Transplantation Center, Fujian Institute of Hematology, Fujian Provincial Key Laboratory on Hematology, Fujian Medical University Union Hospital, Fuzhou, China
5 State Key Laboratory of Medical Genomics, Shanghai Institute of Hematology, National Research Center for Translational Medicine at Shanghai, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China
6 Peking University People’s Hospital, Peking University Institute of Hematology, National Clinical Research Center for Hematologic Disease, Beijing Key Laboratory of Cell and Gene Therapy for Hematologic Malignancies, Peking University, Beijing, China
7 The First Affiliated Hospital of Zhengzhou University, Henan, China
8 Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
9 Nuwacell Biotechnologies Co., Ltd, hefei, China
10 Department of Hematology, The First Affiliated Hospital of USTC, Division of Life Sciences and Medicine, University of Science and Technology of China, Hefei, Anhui, China, hefei, China
11 State Key Laboratory of Experimental Hematology, Haihe Laboratory of Cell Ecosystem, Institute of Hematology & Blood Diseases Hospital, National Clinical Research Center for Blood Diseases, Chinese Academy of Medical Sciences & Peking Union Medical College, Tianjin, China
ABSTRACT
Background: Corticosteroids are the standard first-line therapy for acute graft-versus-host disease (aGVHD). The commonly used second-line options after corticosteroid failure in clinical practice include ruxolitinib, interleukin-2 receptor monoclonal antibodies (IL-2RA) and MTX, which have shown efficacy in 57%~72% of steroid refractory aGVHD patients. The response rate is even lower in patients with gastrointestinal involvement, at only 46%~56%. NCR102 (human induced pluripotent stem cell-derived mesenchymal stromal cells, iMSC) injection has demonstrated therapeutic potential in clinical trials for SR-aGVHD through its immunomodulatory and tissue repair capacities. Yet the effect of NCR102 injection in aGVHD patients who have failed second-line therapies with gastrointestinal involvement remains to be defined.
Subjects and Methods: This multicenter, open-label, single arm phase I/II clinical trial enrolled participants with gastrointestinal aGVHD (GI-aGVHD) who had failed second-line therapies. The safety and efficacy of NCR102 injection added to the best available therapy (BAT) were assessed. Phase I employed a 3+3 dose-escalation design to evaluate two dose levels: 1.0 × 106 cells/kg and 2.0 × 106 cells/kg and confirmed dose expansion at 1.0 × 106 cells/kg. This dose established in Phase I was adopted in Phase II study. Participants who meet the following criteria were eligible for enrollment: after receiving ruxolitinib as the preferred second-line treatment, they demonstrate (1) disease progression within 5 to 7 days; (2) absence of complete remission by day 14; or (3) relapse following an initial response. NCR102 injection was administered twice a week for 4 weeks. Participants with partial response (PR) after the first 4 weeks of treatment received further infusions for an additional 4 weeks. Response was defined as Complete response (CR) in participants who showed complete resolution of all aGVHD symptoms, and PR in participants who showed aGVHD reduction by at least one grade according to the MAGIC criteria, or non-response (NR) by day 28 since the first NCR102 infusion.
Results: A total of 40 participants aged 18-70 years with grade II-IV GI-aGVHD who failed second-line treatment were enrolled in the study (3 participants in each dose group during the phase I dose escalation; 34 in the phase II study with 1.0 × 106 cells/kg per dose). 37 participants with grade II (18.9%), III (18.9%) or IV (62.2%) received target dose of NCR102 infusion at 1.0 × 106 cells/kg, 54.1% of whom were male. The median age and weight were 45 years old (range, 19-60) and 54 kg (range, 34-83) respectively. 32.4% had involvement of ≥2 organs. Among participants who had failed second-line therapies, 43.2% had disease progression within 5–7 days, 5.4% did not achieve CR by day 14, and 51.4% relapsed following initial response. In the 2.0 × 106 cells/kg dose group, 3 male participants were all severe aGVHD with only lower gastrointestinal involvement.
No adverse reactions related to NCR102 infusion were observed in either dose group. Among 37 participants in target dose group, the overall response rate (ORR) at day 28, 56 and 100 were 78.4%, 70.3% and 62.1% respectively, with complete remission rates (CRR) of 59.5%, 59.5% and 56.7%. 86.4% (19/22) of CR patients on Day 28 remained complete response on Day 100. Two patients with PR achieved CR after one additional cycle of NCR102 therapy. Cumulative overall survival (OS) rate at day 100 after NCR102 treatment is 80.0%, while the historic median OS of steroid- and ruxolitinib- refractory GI-aGVHD (grade II-IV) was only 86 days (95% CI: 54–128 days). In the responding patients, the active T cell levels decreased by a mean of 6.38% by day 28, whereas an upward trend (average 10.58% increased) was observed in non-responders. All participants achieving remission of gastrointestinal involvement exhibited a favorable trend in overall response rates. In the 2.0 × 106 cells/kg dose group, the ORR and CRR were 66.7% and 33.3% at 28 days, and both 66.7% at day 56, respectively.
Conclusion: NCR102 injection was safe and effective in patients with grade II-IV GI-aGVHD who had failed second-line therapies, achieving high rate of remission and considerable survival outcomes. These results support NCR102 as a promising therapy and need for further investigation on these aGVHD patient cohort.
DISCLOSURES
Erlie Jiang, MD: No relevant conflicts of interest to declare.